C. H. . Bang, “Ustekinumab Demonstrates Lower Uveitis Risk in Moderate to Severe Psoriasis Patients Compared with Tumor Necrosis Factor-α Inhibitors”, Acta Derm Venereol, vol. 104, p. adv34206, Sep. 2024.